These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25960085)

  • 1. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
    Shibuya K; Misawa S; Kimura H; Noto Y; Sato Y; Sekiguchi Y; Iwai Y; Mitsuma S; Beppu M; Watanabe K; Fujimaki Y; Tsuji Y; Shimizu T; Mizuno T; Nakagawa M; Sawaguchi K; Hanaoka H; Kuwabara S
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):353-8. PubMed ID: 25960085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial.
    Weiss MD; Macklin EA; McIlduff CE; Vucic S; Wainger BJ; Kiernan MC; Goutman SA; Goyal NA; Rutkove SB; Ladha SS; Chen IA; Harms MB; Brannagan TH; Lacomis D; Zivkovic S; Ma M; Wang LH; Simmons Z; Rivner MH; Shefner JM; Cudkowicz ME; Atassi N;
    Muscle Nerve; 2021 Mar; 63(3):371-383. PubMed ID: 33340120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
    Weiss MD; Macklin EA; Simmons Z; Knox AS; Greenblatt DJ; Atassi N; Graves M; Parziale N; Salameh JS; Quinn C; Brown RH; Distad JB; Trivedi J; Shefner JM; Barohn RJ; Pestronk A; Swenson A; Cudkowicz ME;
    Neurology; 2016 Apr; 86(16):1474-81. PubMed ID: 26911633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Motor nerve hyperexcitability in ALS: its pathophysiology and treatment].
    Shibuya K; Misawa S; Kuwabara S
    Rinsho Shinkeigaku; 2014; 54(12):1086-8. PubMed ID: 25672715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
    Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
    EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.
    Adiao KJB; Espiritu AI; Bagnas MAC
    Neurodegener Dis Manag; 2020 Dec; 10(6):397-407. PubMed ID: 32867586
    [No Abstract]   [Full Text] [Related]  

  • 8. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis.
    Kanai K; Shibuya K; Sato Y; Misawa S; Nasu S; Sekiguchi Y; Mitsuma S; Isose S; Fujimaki Y; Ohmori S; Koga S; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):734-8. PubMed ID: 22566594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.
    Vucic S; Lin CS; Cheah BC; Murray J; Menon P; Krishnan AV; Kiernan MC
    Brain; 2013 May; 136(Pt 5):1361-70. PubMed ID: 23616585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Kovalchuk MO; Heuberger JAAC; Sleutjes BTHM; Ziagkos D; van den Berg LH; Ferguson TA; Franssen H; Groeneveld GJ
    Clin Pharmacol Ther; 2018 Dec; 104(6):1136-1145. PubMed ID: 29672831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis.
    Iwai Y; Shibuya K; Misawa S; Sekiguchi Y; Watanabe K; Amino H; Kuwabara S
    PLoS One; 2016; 11(7):e0158596. PubMed ID: 27383069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
    Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
    Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons.
    Shibuya K; Misawa S; Nasu S; Sekiguchi Y; Mitsuma S; Beppu M; Ohmori S; Iwai Y; Ito S; Kanai K; Sato Y; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):969-72. PubMed ID: 23467416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage.
    Kanai K; Kuwabara S; Misawa S; Tamura N; Ogawara K; Nakata M; Sawai S; Hattori T; Bostock H
    Brain; 2006 Apr; 129(Pt 4):953-62. PubMed ID: 16467388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.